Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in heavily pretreated patients with hematological malignancies. Hematology Meeting Reports, [S. l.], v. 1, n. 8, 2009. DOI: 10.4081/hmr.v1i8.297. Disponível em: https://journals.pagepress.org/hmr/article/view/297. Acesso em: 12 aug. 2025.